Abstract
Albumin is a biocompatible, non-immunogenic and versatile drug carrier system. It has been widely used to extend the half-life, enhance stability, provide protection from degradation and allow specific targeting of therapeutic agents to various disease states. Understanding the role of albumin as a drug delivery and distribution system has increased remarkably in the recent years from the development of albumin-binding prodrugs to albumin as a drug carrier system. The extraordinary surface property of albumin makes it possible to bind various endogenous and exogenous molecules. This review succinctly deals with several albumin-drug conjugates and nanoparticles along with their preparation techniques and focuses on surface-modified albumin and targeting of albumin formulation to specific organs and tissues. It also summarizes research efforts on albumin nanoparticles used for delivering drugs to tumor cells and describes their role in permeation through tumor vasculature and in receptor mediated endocytosis, which is also described in this review. The versatility of albumin and ease of preparation makes it a suitable drug carrier system, swhich is the major objective of this review.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Agarwal A, Majumder S, Agrawal H, Majumdar S, Agrawal GP (2011) Cationized albumin conjugated solid lipid nanoparticles as vectors for brain delivery of an anti-cancer drug. Curr Nanosci 7:71–80. https://doi.org/10.2174/157341311794480291
Al-Azzawi S, Masheta DJ (2019) Designing a drug delivery system for improved tumor treatment and targeting by functionalization of a cell-penetrating peptide. J Pharm Invest 49:643–654. https://doi.org/10.1007/s40005-018-00424-w
An F-F, Zhang X-H (2017) Strategies for preparing albumin-based nanoparticles for multifunctional bioimaging and drug delivery. Theranostics 7:3667. https://doi.org/10.7150/thno.19365
Anhorn MG, Wagner S, Kreuter JR, Langer K, Von Briesen H (2008) Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles. Bioconjug Chem 19:2321–2331. https://doi.org/10.1021/bc8002452
Asgharkhani E, Fathi Azarbayjani A, Irani S, Chiani M, Saffari Z, Norouzian D, Akbarzadeh A, Atyabi SM (2018) Artemisinin-loaded niosome and pegylated niosome: physico-chemical characterization and effects on MCF-7 cell proliferation. J Pharm Invest 48:251–256. https://doi.org/10.1007/s40005-017-0331-y
Balan V, Nelson DR, Sulkowski MS, Everson GT, Lambiase LR, Wiesner RH, Dickson RC, Post AB, Redfield RR, Davis GL (2006) A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antiviral Ther 11:35
Bansal R, Prakash J, Ruijter MD, Beljaars L, Poelstra K (2011) Peptide-modified albumin carrier explored as a novel strategy for a cell-specific delivery of interferon gamma to treat liver fibrosis. Mol Pharm 8:1899–1909. https://doi.org/10.1021/mp200263q
Bartneck M, Warzecha KT, Tacke F (2014) Therapeutic targeting of liver inflammation and fibrosis by nanomedicine. Hepatobil Surg Nutr 3:364. https://doi.org/10.3978/j.issn.2304-3881.2014.11.02
Beljaars L, Weert B, Geerts A, Meijer DK, Poelstra K (2003) The preferential homing of a platelet derived growth factor receptor-recognizing macromolecule to fibroblast-like cells in fibrotic tissue. Biochem Pharmacol 66:1307–1317. https://doi.org/10.1016/S0006-2952(03)00445-3
Bern M, Sand KMK, Nilsen J, Sandlie I, Andersen JT (2015) The role of albumin receptors in regulation of albumin homeostasis: Implications for drug delivery. J Control Release 211:144–162. https://doi.org/10.1016/j.jconrel.2015.06.006
Bickel U, Yoshikawa T, Pardridge WM (2001) Delivery of peptides and proteins through the blood–brain barrier. Adv Drug Deliv Rev 46:247–279. https://doi.org/10.1016/S0169-409X(00)00139-3
Boldt J (2010) Use of albumin: an update. Br J Anaesth 104:276–284. https://doi.org/10.1093/bja/aep393
Breton J, Pezzi N, Molinari A, Bonomini L, Lansen J, De Buitrago GG, Prieto I (1995) Prolonged half-life in the circulation of a chemical conjugate between a pro-urokinase derivative and Human Serum Albumin. Eur J Biochem 231:563–569. https://doi.org/10.1111/j.1432-1033.1995.0563d.x
Byeon HJ, Thao LQ, Lee S, Min SY, Lee ES, Shin BS, Choi H-G, Youn YS (2016) Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors. J Control Release 225:301–313. https://doi.org/10.1016/j.jconrel.2016.01.046
Caspersen MB, Kuhlmann M, Nicholls K, Saxton MJ, Andersen B, Bunting K, Cameron J, Howard KA (2017) Albumin-based drug delivery using cysteine 34 chemical conjugates—important considerations and requirements. Ther Deliv 8:511–519. https://doi.org/10.4155/tde-2017-0038
Catanzaro G, Curcio M, Cirillo G, Spizzirri UG, Besharat ZM, Abballe L, Vacca A, Iemma F, Picci N, Ferretti E (2017) Albumin nanoparticles for glutathione-responsive release of cisplatin: New opportunities for medulloblastoma. Int J Pharm 517:168–174. https://doi.org/10.1016/j.ijpharm.2016.12.017
Chang TZ, Stadmiller SS, Staskevicius E, Champion JA (2017) Effects of ovalbumin protein nanoparticle vaccine size and coating on dendritic cell processing. Biomater Sci 5:223–233. https://doi.org/10.1039/c6bm00500d
Choi YH, Han H-K (2018) Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics. J Pharm Invest 48:43–60. https://doi.org/10.1007/s40005-017-0370-4
Choi SH, Byeon HJ, Choi JS, Thao L, Kim I, Lee ES, Shin BS, Lee KC, Youn YS (2015) Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer. J Control Release 197:199–207. https://doi.org/10.1016/j.jconrel.2014.11.008
Cortes J, Saura C (2010) Nanoparticle albumin-bound (nab™)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer. Eur J Cancer Suppl 8:1–10. https://doi.org/10.1016/S1359-6349(10)70002-1
Davis M, Walker G (2018) Recent strategies in spray drying for the enhanced bioavailability of poorly water-soluble drugs. J Control Release 269:110–127. https://doi.org/10.1016/j.jconrel.2017.11.005
Dijk FV, Olinga P, Poelstra K, Beljaars L (2015) Targeted therapies in liver fibrosis: combining the best parts of platelet derived growth factor BB and interferon gamma. Front Med 2:72. https://doi.org/10.3389/fmed.2015.00072
Dong Y, Fu R, Yang J, Ma P, Liang L, Mi Y, Fan D (2019) Folic acid-modified ginsenoside Rg5-loaded bovine serum albumin nanoparticles for targeted cancer therapy in vitro and in vivo. Int J Nanomed 14:6971–6988. https://doi.org/10.2147/IJN.S210882
Dreis S, Rothweiler F, Michaelis M, Cinatl J Jr, Kreuter J, Langer K (2007) Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. Int J Pharm 341:207–214. https://doi.org/10.1016/j.ijpharm.2007.03.036
Duttaroy A, Kanakaraj P, Osborn BL, Schneider H, Pickeral OK, Chen C, Zhang G, Kaithamana S, Singh M, Schulingkamp R, Crossan D, Bock J, Kaufman TE, Reavey P, Carey-Barber M, Krishnan SR, Garcia A, Murphy K, Siskind JK, Mclean MA, Cheng S, Ruben S, Birse CE, Blondel O (2005) Development of a long-acting insulin analog using albumin fusion technology. Diabetes 54:251–258. https://doi.org/10.2337/diabetes.54.1.251
Elsadek B, Graeser R, Warnecke A, Unger C, Saleem T, El-Melegy N, Madkor H, Kratz F (2010) Optimization of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen. ACS Med Chem Lett 1:234–238. https://doi.org/10.1021/ml100060m
Elsadek B, Graeser R, Esser N, Schäfer-Obodozie C, Tsurumi C, Ajaj KA, Warnecke A, Unger C, Saleem T, Kratz F (2011) In vivo evaluation of a novel albumin-binding prodrug of doxorubicin in an orthotopic mouse model of prostate cancer (LNCaP). Prostate Cancer Prostatic Dis 14:14. https://doi.org/10.1038/pcan.2010.43
Elzoghby AO, Samy WM, Elgindy NA (2012) Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release 157:168–182. https://doi.org/10.1016/j.jconrel.2011.07.031
Fahrländer E, Schelhaas S, Jacobs A, Langer K (2015) PEGylated human serum albumin (HSA) nanoparticles: preparation, characterization and quantification of the PEGylation extent. Nanotechnology 26:145103. https://doi.org/10.1088/0957-4484/26/14/145103
Fasano M, Curry S, Terreno E, Galliano M, Fanali G, Narciso P, Notari S, Ascenzi P (2005) The extraordinary ligand binding properties of human serum albumin. IUBMB Life 57:787–796. https://doi.org/10.1080/15216540500404093
Ghosh D, Peng X, Leal J, Mohanty RP (2018) Peptides as drug delivery vehicles across biological barriers. J Pharm Invest 48:89–111. https://doi.org/10.1007/s40005-017-0374-0
Gou S, Chen Q, Liu Y, Zeng L, Song H, Xu Z, Kang Y, Li C, Xiao B (2018) Green fabrication of ovalbumin nanoparticles as natural Polyphenol carriers for ulcerative colitis therapy. ACS Sustain Chem Eng 6:12658–12667. https://doi.org/10.1021/acssuschemeng.8b01613
Hagens WI, Mattos A, Greupink R, De Jager-Krikken A, Reker-Smit C, Van Loenen-Weemaes A, Gouw AS, Poelstra K, Beljaars L (2007) Targeting 15d-prostaglandin J 2 to hepatic stellate cells: two options evaluated. Pharm Res 24:566–574. https://doi.org/10.1007/s11095-006-9175-2
Hawkins MJ, Soon-Shiong P, Desai N (2008) Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 60:876–885. https://doi.org/10.1016/j.addr.2007.08.044
He S, Lin Q, Qu M, Wang L, Deng L, Xiao L, Zhang Z, Zhang L (2018) Liver-targeted co-delivery of entecavir and glycyrrhetinic acid based on albumin nanoparticle to enhance the accumulation of entecavir. Mol Pharm 15:3953–3961. https://doi.org/10.1021/acs.molpharmaceut.8b00408
Hermanson GT (2013) Vaccines and Immunogen Conjugates. In: Hermanson GT (ed) Bioconjugate techniques, 3rd edn. Academic Press, Amsterdam, pp 839–865
Hidalgo M, Plaza C, Musteanu M, Illei P, Brachmann CB, Heise C, Pierce D, Lopez-Casas PP, Menendez C, Tabernero J, Romano A, Wei X, Lopez-Rios F, Von Hoff DD (2015) SPARC expression did not predict efficacy of nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer in an exploratory analysis of the phase III MPACT trial. Clin Cancer Res 21:4811–4818. https://doi.org/10.1158/1078-0432.Ccr-14-3222
Hoogenboezem EN, Duvall CL (2018) Harnessing albumin as a carrier for cancer therapies. Adv Drug Deliv Rev 130:73–89. https://doi.org/10.1016/j.addr.2018.07.011
Huang X, Tu Z, Xiao H, Wang H, Zhang L, Hu Y, Zhang Q, Niu P (2012) Characteristics and antioxidant activities of ovalbumin glycated with different saccharides under heat moisture treatment. Food Res Int 48:866–872. https://doi.org/10.1016/j.foodres.2012.06.036
Huntington JA, Stein PE (2001) Structure and properties of ovalbumin. J Chromatogr B 756:189–198. https://doi.org/10.1016/S0378-4347(01)00108-6
Jun JY, Nguyen HH, Chun HS, Kang B-C, Ko S (2011) Preparation of size-controlled bovine serum albumin (BSA) nanoparticles by a modified desolvation method. Food Chem 127:1892–1898. https://doi.org/10.1016/j.foodchem.2011.02.040
Karimi M, Bahrami S, Ravari SB, Zangabad PS, Mirshekari H, Bozorgomid M, Shahreza S, Sori M, Hamblin MR (2016) Albumin nanostructures as advanced drug delivery systems. Expert Opin Drug Del 13:1609–1623. https://doi.org/10.1080/17425247.2016.1193149
Kavanagh GM, Clark AH, Ross-Murphy SB (2000) Heat-induced gelation of globular proteins: part 3. Molecular studies on low pH β-lactoglobulin gels. Int J Biol Macromol 28:41–50. https://doi.org/10.1016/S0141-8130(00)00144-6
Kim B, Lee C, Lee ES, Shin BS, Youn YS (2016) Paclitaxel and curcumin co-bound albumin nanoparticles having antitumor potential to pancreatic cancer. Asian J Pharm Sci 11:708–714. https://doi.org/10.1016/j.ajps.2016.05.005
Kouchakzadeh H, Shojaosadati SA, Tahmasebi F, Shokri F (2013) Optimization of an anti-HER2 monoclonal antibody targeted delivery system using PEGylated human serum albumin nanoparticles. Int J Pharm 447:62–69. https://doi.org/10.1016/j.ijpharm.2013.02.043
Kratz F (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 132:171–183. https://doi.org/10.1016/j.jconrel.2008.05.010
Kreuter J, Hekmatara T, Dreis S, Vogel T, Gelperina S, Langer K (2007) Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J Control Release 118:54–58. https://doi.org/10.1016/j.jconrel.2006.12.012
Lam PL, Kok SHL, Gambari R, Kok TW, Leung HY, Choi KL, Wong CS, Hau DKP, Wong WY, Lam KH, Bian ZX, Lee KKH, Chui CH (2015) Evaluation of berberine/bovine serum albumin nanoparticles for liver fibrosis therapy. Green Chem 17:1640–1646. https://doi.org/10.1039/C4GC01815J
Larsen MT, Kuhlmann M, Hvam ML, Howard KA (2016) Albumin-based drug delivery: harnessing nature to cure disease. Mol Cell Ther 4:3. https://doi.org/10.1186/s40591-016-0048-8
Le Thao Q, Byeon HJ, Lee C, Lee S, Lee ES, Choi HG, Park ES, Youn YS (2016) Pharmaceutical potential of tacrolimus-loaded albumin nanoparticles having targetability to rheumatoid arthritis tissues. Int J Pharm 497:268–276. https://doi.org/10.1016/j.ijpharm.2015.12.004
Le Q-V, Choi J, Oh Y-K (2018) Nano delivery systems and cancer immunotherapy. J Pharm Invest 48:527–539. https://doi.org/10.1007/s40005-018-0399-z
Lee P, Wu X (2015) Modifications of human serum albumin and their binding effect. Curr Pharm Des 21:1862–1865. https://doi.org/10.2174/1381612821666150302115025
Lee ES, Youn YS (2016) Albumin-based potential drugs: focus on half-life extension and nanoparticle preparation. J Pharm Invest 46:305–315. https://doi.org/10.1007/s40005-016-0250-3
Lee SH, Heng D, Ng WK, Chan H-K, Tan RBH (2011) Nano spray drying: A novel method for preparing protein nanoparticles for protein therapy. Int J Pharm 403:192–200. https://doi.org/10.1016/j.ijpharm.2010.10.012
Lee JE, Kim MG, Jang YL, Lee MS, Kim NW, Yin Y, Lee JH, Lim SY, Park JW, Kim J (2018) Self-assembled PEGylated albumin nanoparticles (SPAN) as a platform for cancer chemotherapy and imaging. Drug Del 25:1570–1578. https://doi.org/10.1080/10717544.2018.1489430
Li C, Zhang D, Guo H, Hao L, Zheng D, Liu G, Shen J, Tian X, Zhang Q (2013) Preparation and characterization of galactosylated bovine serum albumin nanoparticles for liver-targeted delivery of oridonin. Int J Pharm 448:79–86. https://doi.org/10.1016/j.ijpharm.2013.03.019
Li B, Chen A, Zou S, Wu J, Wang H, Chen R, Luo M (2019) Albumin fusion improves the pharmacokinetics and in vivo antitumor efficacy of canine interferon gamma. Int J Pharm 558:404–412. https://doi.org/10.1016/j.ijpharm.2018.12.081
Liang J, Zhu Y, Gao C, Ling C, Qin J, Wang Q, Huang Y, Lu W, Wang J (2019) Menthol-modified BSA nanoparticles for glioma targeting therapy using an energy restriction strategy. NPG Asia Mater 11:38. https://doi.org/10.1038/s41427-019-0138-6
Lin T, Zhao P, Jiang Y, Tang Y, Jin H, Pan Z, He H, Yang VC, Huang Y (2016) Blood–brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy. ACS Nano 10:9999–10012. https://doi.org/10.1021/acsnano.6b04268
Loureiro A, Azoia NG, Gomes AC, Cavaco-Paulo A (2016) Albumin-based nanodevices as drug carriers. Curr Pharm Des 22:1371–1390. https://doi.org/10.2174/1381612822666160125114900
Luppi B, Bigucci F, Corace G, Delucca A, Cerchiara T, Sorrenti M, Catenacci L, Di Pietra AM, Zecchi V (2011) Albumin nanoparticles carrying cyclodextrins for nasal delivery of the anti-Alzheimer drug tacrine. Eur J Pharm Sci 44:559–565. https://doi.org/10.1016/j.ejps.2011.10.002
Löw K, Wacker M, Wagner S, Langer K, Von Briesen H (2011) Targeted human serum albumin nanoparticles for specific uptake in EGFR Expressing colon carcinoma cells. Nanomed Nanotech Bio Med 7:454–463. https://doi.org/10.1016/j.nano.2010.12.003
Marty J (1978) Nanoparticles-a new colloidal drug delivery system. Pharm Acta Helv 53:17–23
Masters K (1987) Spray drying handbook, 4th edn. Halstead Press, pp 172–173
Melgert BN, Olinga P, Van Der Laan JM, Weert B, Cho J, Schuppan D, Groothuis GM, Meijer DK, Poelstra K (2001) Targeting dexamethasone to Kupffer cells: effects on liver inflammation and fibrosis in rats. Hepatology 34:719–728. https://doi.org/10.1053/jhep.2001.27805
Mersfelder TL, Nichols WH (2016) Gabapentin: abuse, dependence, withdrawal. Ann Pharmacother 50:229–233. https://doi.org/10.1177/1060028015620800
Michaelis K, Hoffmann MM, Dreis S, Herbert E, Alyautdin RN, Michaelis M, Kreuter J, Langer K (2006) Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther 317:1246–1253. https://doi.org/10.1124/jpet.105.097139
Miele E, Spinelli GP, Miele E, Tomao F, Tomao S (2009) Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer. Int J Nanomed 4:99. https://doi.org/10.2147/IJN.S3061
Mishra V, Mahor S, Rawat A, Gupta PN, Dubey P, Khatri K, Vyas SP (2006) Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. J Drug Target 14:45–53. https://doi.org/10.1080/10611860600612953
Moman RN, Varacallo M (2018) Physiology, Albumin. StatPearls [Internet]. StatPearls Publishing, Treasure Island
Monahan FJ, German JB, Kinsella JE (1995) Effect of pH and temperature on protein unfolding and thiol/disulfide interchange reactions during heat-induced gelation of whey proteins. J Agric Food Chem 43:46–52. https://doi.org/10.1021/jf00049a010
Niknejad H, Mahmoudzadeh R (2015) Comparison of different crosslinking methods for preparation of docetaxelloaded albumin nanoparticles. Iran J Pharm Res 14:385. https://doi.org/10.22037/ijpr.2015.1639
Nnyigide OS, Oh Y, Song HY, Park E-K, Choi S-H, Hyun K (2017) Effect of urea on heat-induced gelation of bovine serum albumin (BSA) studied by rheology and small angle neutron scattering (SANS). Korea-Aust Rheol J 29:101–113. https://doi.org/10.1007/s13367-017-0012-4
Ouyang Q-Q, Zhao S, Li S-D, Song C (2017) Application of chitosan, chitooligosaccharide, their derivatives in the treatment of Alzheimer’s disease. Mar Drugs 15:322. https://doi.org/10.3390/md15110322
Perinelli DR, Cespi M, Bonacucina G, Palmieri GFJOPI (2019) PEGylated polylactide (PLA) and poly (lactic-co-glycolic acid) (PLGA) copolymers for the design of drug delivery systems. J Pharm Invest 49:443–458. https://doi.org/10.1007/s40005-019-00442-2
Pes L, Koester SD, Magnusson JP, Chercheja S, Medda F, Abu Ajaj K, Rognan D, Daum S, Nollmann FI, Garcia Fernandez J, Perez Galan P, Walter H-K, Warnecke A, Kratz F (2019) Novel auristatin E-based albumin-binding prodrugs with superior anticancer efficacy in vivo compared to the parent compound. J Control Release 296:81–92. https://doi.org/10.1016/j.jconrel.2019.01.010
Reis CP, Neufeld RJ, Ribeiro AJ, Veiga F (2006) Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomed: Nanotech Bio Med 2:8–21. https://doi.org/10.1016/j.nano.2005.12.003
Qi J, Yao P, He F, Yu C, Huang C (2010) Nanoparticles with dextran/chitosan shell and BSA/chitosan core—doxorubicin loading and delivery. Int J Pharm 393:177–185. https://doi.org/10.1016/j.ijpharm.2010.03.063
Qi L, Guo Y, Luan J, Zhang D, Zhao Z, Luan Y (2014) Folate-modified bexarotene-loaded bovine serum albumin nanoparticles as a promising tumor-targeting delivery system. J Mater Chem B 2:8361–8371. https://doi.org/10.1039/C4TB01102C
Qi WW, Yu HY, Guo H, Lou J, Wang ZM, Liu P, Sapin-Minet A, Maincent P, Hong XC, Hu XM, Xiao YL (2015) Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy. Mol Pharm 12:675–683. https://doi.org/10.1021/mp500394v
Ruan C, Liu L, Lu Y, Zhang Y, He X, Chen X, Zhang Y, Chen Q, Guo Q, Sun T (2018) Substance P-modified human serum albumin nanoparticles loaded with paclitaxel for targeted therapy of glioma. Acta Pharm Sin B 8:85–96. https://doi.org/10.1039/C4TB01102C
Ruiz-Peña M, Oropesa-Nuñez R, Pons T, Louro SRW, Pérez-Gramatges A (2010) Physico-chemical studies of molecular interactions between non-ionic surfactants and bovine serum albumin. Colloids Surf B 75:282–289. https://doi.org/10.1016/j.colsurfb.2009.08.046
Safavi MS, Shojaosadati SA, Yang HG, Kim Y, Park EJ, Lee KC, Na DH (2017) Reducing agent-free synthesis of curcumin-loaded albumin nanoparticles by self-assembly at room temperature. Int J Pharm 529:303–309. https://doi.org/10.1016/j.ijpharm.2017.06.087
Sanchez-Covarrubias L, Slosky LM, Thompson BJ, Davis TP, Ronaldson PT (2014) Transporters at CNS barrier sites: obstacles or opportunities for drug delivery? Curr Pharm Des 20:1422–1449. https://doi.org/10.2174/13816128113199990463
Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L (2016) Nanoparticle-mediated brain drug delivery: overcoming blood–brain barrier to treat neurodegenerative diseases. J Control Release 235:34–47. https://doi.org/10.1016/j.jconrel.2016.05.044
Schmid B, Chung D-E, Warnecke A, Fichtner I, Kratz F (2007) Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy. Bioconjug Chem 18:702–716. https://doi.org/10.1021/bc0602735
Schulte S (2008) Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa. Thromb Res 122:S14–S19. https://doi.org/10.1016/S0049-3848(08)70029-X
Schulte S (2009) Half-life extension through albumin fusion technologies. Thromb Res 124:S6–S8. https://doi.org/10.1016/S0049-3848(09)70157-4
Schulte S (2013) Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII. Thromb Res 131:S2–S6. https://doi.org/10.1016/S0049-3848(13)70150-6
Shargh VH, Hondermarck H, Liang M (2016) Albumin hybrid nanoparticles loaded with tyrosine kinase a inhibitor GNF-5837 for targeted inhibition of breast cancer cell growth and invasion. Int J Pharm 515:527–534. https://doi.org/10.1016/j.ijpharm.2016.10.057
Sharma G, Sharma AR, Lee S-S, Bhattacharya M, Nam J-S, Chakraborty C (2019) Advances in nanocarriers enabled brain targeted drug delivery across blood brain barrier. Int J Pharm 559:360–372. https://doi.org/10.1016/j.ijpharm.2019.01.056
Sheffield WP, Smith I, Syed S, Bhakta V (2001) Prolonged in vivo anticoagulant activity of a hirudin–albumin fusion protein secreted from Pichia pastoris. Blood Coagul Fibrinolysis 12:433–443. https://doi.org/10.1097/00001721-200109000-00003
Shimada K, Cheftel JC (1989) Sulfhydryl group/disulfide bond interchange reactions during heat-induced gelation of whey protein isolate. J Agric Food Chem 37:161–168. https://doi.org/10.1021/jf00085a038
Sleep D (2015) Albumin and its application in drug delivery. Expert Opin Drug Deliv 12:793–812. https://doi.org/10.1517/17425247.2015.993313
Soon-Shiong P, Desai NP, Grinstaff MW, Sandford PA, Suslick KS (1996) Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor. Google Patents
Stehle G, Sinn H, Wunder A, Schrenk HH, Schütt S, Maier-Borst W, Heene DL (1997a) The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats. Anticancer Drugs 8:677–685. https://doi.org/10.1097/00001813-199708000-00006
Stehle G, Wunder A, Sinn H, Schrenk HH, Schütt S, Frei E, Hartung G, Maier-Borst W, Heene DL (1997b) Pharmacokinetics of methotrexate-albumin conjugates in tumor-bearing rats. Anticancer Drugs 8:835–844. https://doi.org/10.1097/00001813-199710000-00004
Sugio S, Kashima A, Mochizuki S, Noda M, Kobayashi K (1999) Crystal structure of human serum albumin at 25 A resolution. Protein Eng 12:439–446. https://doi.org/10.1093/protein/12.6.439
Surendran SP, Thomas RG, Moon MJ, Jeong YY (2017) Nanoparticles for the treatment of liver fibrosis. Int J Nanomed 12:6997. https://doi.org/10.2147/IJN.S145951
Taneja N, Singh KK (2018) Rational design of polysorbate 80 stabilized human serum albumin nanoparticles tailored for high drug loading and entrapment of irinotecan. Int J Pharm 536:82–94. https://doi.org/10.1016/j.ijpharm.2017.11.024
Thao LQ, Lee C, Kim B, Lee S, Kim TH, Kim JO, Lee ES, Oh KT, Choi H-G, Yoo SD, Youn YS (2017) Doxorubicin and paclitaxel co-bound lactosylated albumin nanoparticles having targetability to hepatocellular carcinoma. Colloids Surf B 152:183–191. https://doi.org/10.1016/j.colsurfb.2017.01.017
Thöle M, Nobmann S, Huwyler J, Bartmann A, Fricker G (2002) Uptake of cationized albumin coupled liposomes by cultured porcine brain microvessel endothelial cells and intact brain capillaries. J Drug Target 10:337–344. https://doi.org/10.1080/10611860290031840
Tijink BM, Laeremans T, Budde M, Walsum MS-V, Dreier T, De Haard HJ, Leemans CR, Van Dongen G (2008) Improved tumor targeting of anti–epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular nanobody technology. Mol Cancer Ther 7:2288–2297. https://doi.org/10.1158/1535-7163.MCT-07-2384
Topală T, Bodoki A, Oprean L, Oprean R (2014) Bovine serum albumin interactions with metal complexes. Cluj Med 87:215–219. https://doi.org/10.15386/cjmed-357
Von Storp B, Engel A, Boeker A, Ploeger M, Langer K (2012) Albumin nanoparticles with predictable size by desolvation procedure. J Microencapsul 29:138–146. https://doi.org/10.3109/02652048.2011.635218
Wagner S, Rothweiler F, Anhorn MG, Sauer D, Riemann I, Weiss EC, Katsen-Globa A, Michaelis M, Cinatl J, Schwartz D, Kreuter J, Von Briesen H, Langer K (2010) Enhanced drug targeting by attachment of an anti αv integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials 31:2388–2398. https://doi.org/10.1016/j.biomaterials.2009.11.093
Wagner S, Zensi A, Wien SL, Tschickardt SE, Maier W, Vogel T, Worek F, Pietrzik CU, Kreuter J, Von Briesen H (2012) Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood-brain barrier model. PLoS ONE 7:e32568. https://doi.org/10.1371/journal.pone.0032568
Wang RQ, Yin YJ, Li H, Wang Y, Pu JJ, Wang R, Dou HJ, Song CJ, Wang RY (2013a) Comparative study of the interactions between ovalbumin and three alkaloids by spectrofluorimetry. Mol Biol Rep 40:3409–3418. https://doi.org/10.1007/s11033-012-2418-x
Wang W, Huang Y, Zhao S, Shao T, Cheng Y (2013b) Human serum albumin (HSA) nanoparticles stabilized with intermolecular disulfide bonds. Chem Commun 49:2234–2236. https://doi.org/10.1039/C3CC38397K
Wang N, Sun P, Lv M, Tong G, Jin X, Zhu X (2017) Mustard-inspired delivery shuttle for enhanced blood-brain barrier penetration and effective drug delivery in glioma therapy. Biomater Sci 5:1041–1050. https://doi.org/10.1039/c7bm00133a
Wang H, Sun S, Zhang Y, Wang J, Zhang S, Yao X, Chen L, Gao Z, Xie B (2019) Improved drug targeting to liver tumor by sorafenib-loaded folate-decorated bovine serum albumin nanoparticles. Drug Deliv 26:89–97. https://doi.org/10.1080/10717544.2018.1561766
Wartlick H, Michaelis K, Balthasar S, Strebhardt K, Kreuter J, Langer K (2004) Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J Drug Target 12:461–471. https://doi.org/10.1080/10611860400010697
Weber C, Coester C, Kreuter J, Langer K (2000) Desolvation process and surface characterisation of protein nanoparticles. Int J Pharm 194:91–102. https://doi.org/10.1016/S0378-5173(99)00370-1
Whiteside T (2008) The tumor microenvironment and its role in promoting tumor growth. Oncogene 27:5904. https://doi.org/10.1038/onc.2008.271
Wilson B, Lavanya Y, Priyadarshini S, Ramasamy M, Jenita JL (2014) Albumin nanoparticles for the delivery of gabapentin: preparation, characterization and pharmacodynamic studies. Int J Pharm 473:73–79. https://doi.org/10.1016/j.ijpharm.2014.05.056
Wong LR, Ho PC (2018) Role of serum albumin as a nanoparticulate carrier for nose-to-brain delivery of R-flurbiprofen: implications for the treatment of Alzheimer's disease. J Pharm Pharmacol 70:59–69. https://doi.org/10.1111/jphp.12836
Wunder A, Stehle G, Schrenk HH, Hartung G, Heene DL, Maier-Borst W, Sinn H (1998) Antitumor activity of methotrexate-albumin conjugates in rats bearing a Walker-256 carcinoma. Int J Cancer 76:884–890. https://doi.org/10.1002/(SICI)1097-0215(19980610)76:6%3C884:AID-IJC19%3E3.0.CO;2-2
Xu R, Fisher M, Juliano RL (2011) Targeted albumin-based nanoparticles for delivery of amphipathic drugs. Bioconjug Chem 22:870–878. https://doi.org/10.1021/bc1002295
Yang R, Zheng Y, Wang Q, Zhao L (2018) Curcumin-loaded chitosan–bovine serum albumin nanoparticles potentially enhanced Aβ 42 phagocytosis and modulated macrophage polarization in Alzheimer’s disease. Nanoscale Res Lett. https://doi.org/10.1186/s11671-018-2759-z13:330
Yardley DA (2013) nab-Paclitaxel mechanisms of action and delivery. J Control Release 170:365–372. https://doi.org/10.1016/j.jconrel.2013.05.041
Yewale C, Baradia D, Vhora I, Misra A (2013) Proteins: emerging carrier for delivery of cancer therapeutics. Expert Opin Drug Deliv 10:1429–1448. https://doi.org/10.1517/17425247.2013.805200
Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, Wagner S, Büchel C, Von Briesen H, Kreuter J (2009) Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Control Release 137:78–86. https://doi.org/10.1016/j.jconrel.2009.03.002
Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, Büchel C, Kreuter J (2010) Human serum albumin nanoparticles modified with apolipoprotein AI cross the blood-brain barrier and enter the rodent brain. J Drug Target 18:842–848. https://doi.org/10.3109/1061186X.2010.513712
Zhao S, Wang W, Huang Y, Fu Y, Cheng Y (2014) Paclitaxel loaded human serum albumin nanoparticles stabilized with intermolecular disulfide bonds. Med Chem Comm 5:1658–1663. https://doi.org/10.1039/C4MD00200H
Zhao L, Zhou Y, Gao Y, Ma S, Zhang C, Li J, Wang D, Li X, Li C, Liu Y, Li X (2015) Bovine serum albumin nanoparticles for delivery of tacrolimus to reduce its kidney uptake and functional nephrotoxicity. Int J Pharm 483:180–187. https://doi.org/10.1016/j.ijpharm.2015.02.018
Acknowledgements
This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Sciences, ICT & Future Planning (NRF-2013R1A1A2012193, NRF-2016R1D1A1B01015369) and the ministry of Education (NRF-2016R1A6A1A03011325).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Authors declare no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Lamichhane, S., Lee, S. Albumin nanoscience: homing nanotechnology enabling targeted drug delivery and therapy. Arch. Pharm. Res. 43, 118–133 (2020). https://doi.org/10.1007/s12272-020-01204-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-020-01204-7